Adam H. Hart
- Cancer Research top 5%
- Oncology top 5%
- Molecular Biology top 5%
- Renal and related cancers 5
- CRISPR and Genetic Engineering 3
- Pluripotent Stem Cells Research 2
- Epigenetics and DNA Methylation 2
- Cancer-related gene regulation 2
- Developmental Biology and Gene Regulation 2
- Hematology top 5%
- Platelet Disorders and Treatments 2
- Genetics top 5%
-
- Galectins and Cancer Biology 1
Adam H. Hart
17 papers receiving 2.4k citations
Hit Papers
Peers
Comparison fields: 5 of 92
- Cancer Research 524
- Oncology 873
- Molecular Biology 1.7k
- Hematology 176
- Genetics 393
Countries citing papers authored by Adam H. Hart
This map shows the geographic impact of Adam H. Hart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam H. Hart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam H. Hart more than expected).
Fields of papers citing papers by Adam H. Hart
This network shows the impact of papers produced by Adam H. Hart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam H. Hart. The network helps show where Adam H. Hart may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Adam H. Hart, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 13 | |
| 2 | 2018 | 8 | |
| 3 | 2017 | 24 | |
| 4 | 2014 | 191 | |
| 5 | 2013 | 14 | |
| 6 | 2011 | 25 | |
| 7 | Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriersbreakdown → | 2009 | 1048 |
| 8 | 2006 | 9 | |
| 9 | 2005 | 196 | |
| 10 | 2005 | 48 | |
| 11 | 2005 | 21 | |
| 12 | 2004 | 260 | |
| 13 | 2003 | 0 | |
| 14 | 2002 | 32 | |
| 15 | 2002 | 178 | |
| 16 | 2000 | 26 | |
| 17 | 2000 | 289 | |
| 18 | Human ERG is a proto-oncogene with mitogenic and transforming activity. | 1995 | 47 |
About Adam H. Hart
Adam H. Hart is a scholar working on Aging, Molecular Biology, Genetics, Hematology and Biophysics, having authored 18 papers that have together received 2.4k indexed citations. Recurring topics across this work include Renal and related cancers (5 papers), CRISPR and Genetic Engineering (3 papers), Pluripotent Stem Cells Research (2 papers), Platelet Disorders and Treatments (2 papers), Epigenetics and DNA Methylation (2 papers), Cancer-related gene regulation (2 papers), Developmental Biology and Gene Regulation (2 papers) and Galectins and Cancer Biology (1 paper). The work is most often cited by research in Cancer Research (524 citations), Oncology (873 citations), Molecular Biology (1.7k citations), Hematology (176 citations) and Genetics (393 citations). Adam H. Hart has collaborated with scholars based in Australia, United States and Canada. Frequent co-authors include Lynne Hartley, Lorraine Robb, David Gyorki, Stephen B. Fox, Max Yan, Heather Thorne, Melissa A. Brown, Natasha C. Forrest, Elgene Lim and Teresa Ward. Their work appears in journals such as Development, Proceedings of the National Academy of Sciences, Cancer, Scientific Reports and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.